Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

Inclusion Criteria: * A history of persistent central serous chorioretinopathy present for at least 3 months Best-corrected visual acuity (BCVA) of 20/40 (73 letters on the ETDRS chart) to light perception as measured by ETDRS protocol refraction. * No signs of choroidal neovascularization * Documented subfoveal fluid by OCT * Active leak associated with the subfoveal fluid * The ability and willingness to provide written informed consent Exclusion Criteria: * Prior treatment with laser or PDT * Have uncontrolled hypertension * Have a history of thromboembolic events including stroke, transient ischemic attacks, and myocardial infarction * Have use of or need for continued anticoagulation therapy, except aspirin 325 mg/day. * Are receiving or require chronic concomitant therapy with systemic (\> 5 mg) or topical ocular corticosteroids. Chronic concomitant therapy is defined as multiple doses taken daily for 14 or more consecutive days at any time within 6 months prior to screening * Previously vitrectomized eyes. * Had allergic reactions to fluorescein dye or lack of venous access. * Any other additional ocular diseases which could irreversibly compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy (AION), age related macular degeneration (AMD), retinal detachment, severe cataracts, etc. * An anticipated need for ocular surgery during the duration of the trial. * Within 1 month prior to screening, have had intra ocular surgeri…